技术评估：MG-98，甲基基因公司。

EPIX Medical Inc, Cambridge, MA 02142-1118, USA.

Curr Opin Mol Ther. 2001 Dec;3(6):599-604.

MethylGene and MGI Pharma are codeveloping MG-98, a second-generation antisense oligonucleotide which inhibits mRNA produced by the DNA methyltransferase gene, for the potential treatment of solid tumors. A phase II trial in recurrent or metastatic squamous cell cancer of the head and neck was initiated in November 2000 [390195] and a phase II trial in patients with advanced and/or metastatic renal cell carcinoma was initiated in August 2001 [419943]. In November 2001, a company representative stated that phase II data would be available in the first half of 2002 [429849]. In April 2001, MethylGene received US-06184211, entitled 'Inhibition of DNA methyltransferase'. This patent covers the administration of an agent that could help the human body to restore normally occurring mechanisms to combat or terminate the growth of cancerous tumors [407067], [407068]. The company has also been awarded US-06221849 entitiled, 'DNA methyltransferase genomic sequences and antisense oligonucleotides', and US-06066625 (WO-09940186), claiming optimized antisense oligos complementary to DNA methyltransferase sequences [427216], [427218].

甲基基因公司（MethylGene）和 MGI 制药公司正在共同开发 MG - 98，这是一种第二代反义寡核苷酸，可抑制由 DNA 甲基转移酶基因产生的信使核糖核酸（mRNA），用于实体瘤的潜在治疗。2000 年 11 月启动了一项针对复发性或转移性头颈部鳞状细胞癌的 II 期试验[390195]，2001 年 8 月启动了一项针对晚期和/或转移性肾细胞癌患者的 II 期试验[419943]。2001 年 11 月，公司代表表示 II 期数据将于 2002 年上半年公布[429849]。2001 年 4 月，甲基基因公司获得了美国专利 06184211，题为“DNA 甲基转移酶的抑制”。该专利涵盖了一种药物的给药方法，该药物可帮助人体恢复正常的机制以对抗或终止癌性肿瘤的生长[407067]，[407068]。该公司还获得了美国专利 06221849，题为“DNA 甲基转移酶基因组序列和反义寡核苷酸”，以及美国专利 06066625（WO - 09940186），该专利主张与 DNA 甲基转移酶序列互补的优化反义寡核苷酸[427216]，[427218]。